Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan sues over Prilosec OTC

Executive Summary

Procter & Gamble's Prilosec OTC is falsely represented as identical to AstraZeneca's prescription version of the proton pump inhibitor, Mylan alleges in a Manhattan federal court lawsuit. Mylan also recently submitted a study to FDA that the company asserts demonstrates OTC omeprazole is not bioequivalent to Prilosec. P&G maintains the Rx and OTC 20 mg formulations are the same. Mylan alleges P&G's claims will divert sales from its own generic omeprazole, which launched "at risk" in August (1"The Pink Sheet" Aug. 11, 2003, p. 11)...

You may also be interested in...



Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold

Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

UsernamePublicRestriction

Register

PS043135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel